• Home
  • Products
  • About
  • Contact

autolus therapeutics to host investor conference calls

Current Location : Home > autolus therapeutics to host investor conference calls

  • Autolus Therapeutics to host Investor Conference Calls

    Autolus Therapeutics to host Investor Conference Calls through June LONDON May 26 2020 -- Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing

    Get Price
  • Autolus Therapeutics reschedules its investor EHA

    Jun 08 2020 · Autolus Therapeutics reschedules its investor EHA conference call Conference call and webcast to be held Friday June 12 2020 at 07 30 am

    Get Price
  • Syncona Ltd. (via Public) / Autolus Therapeutics to host

    Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in

    Get Price
  • Autolus Therapeutics Limited (spons. ADRs) hosts

    Mar 03 2021 · The company Autolus Therapeutics Limited (spons. ADRs) is set to host investors and clients on a conference call on 3/4/2021 10 26 30 PM. The call comes after the company s earnings which are

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · 7 December 2020Dr. Christian Itin chairman and chief executive officer along with the Autolus clinical team will host an investor call and webcast at 4.00 pm ET 9.00 pm GMT to discuss

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · LONDON Nov. 17 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference November 17 2020 at 7 00 AM EST

    Get Price
  • Autolus Therapeutics reschedules its investor EHA

    Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that it has rescheduled its investor conference call to discuss data at the European Hematology Association EHA25 Virtual Congress to 12 June 2020 at 7.30 am EDT 12.30 pm BST.

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    LONDON Sept. 08 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · 1 June 2020Dr. Christian Itin chairman and chief executive officer along with the AUTO3 clinical team will host an investor call and webcast at 8.30 am EDT 1.30 pm BST to discuss presentations related to its AUTO3 program the company s CAR T cell therapy being investigated in the Alexander study a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL)

    Get Price
  • Syncona Ltd. (via Public) / Autolus Therapeutics to host

    Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September

    Get Price
  • Autolus AutolusArix Bioscience

    Apr 01 2021 · Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September. Portfolio Company. Autolus Therapeutics to host Investor Conference Calls through June. Portfolio Company. 22nd May 2020. Autolus Notice of Annual General Meeting (AGM) on Thursday June

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September September 8 2020. LONDON Sept. 08 2020(GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference

    Get Price
  • Autolus Therapeutics to Report First Quarter 2020

    After the conference call a replay will be available for one week. To access the replay please dial (855) for U.S. and Canada callers or (404) for international callers. Please

    Get Price
  • Autolus Therapeutics Limited (spons. ADRs) hosts

    Mar 03 2021 · The company Autolus Therapeutics Limited (spons. ADRs) is set to host investors and clients on a conference call on 3/4/2021 10 26 30 PM. The call comes after the company s earnings which are

    Get Price
  • Autolus Therapeutics to Report Second Quarter 2020

    LONDON July 30 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · --Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host investor conference calls

    Get Price
  • Autolus Therapeutics to Report First Quarter 2020

    After the conference call a replay will be available for one week. To access the replay please dial (855) for U.S. and Canada callers or (404) for international callers. Please

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host investor conference calls through June. 1 June 2020

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference November 17 2020 at 7 00 AM EST

    Get Price
  • Autolus Therapeutics reschedules its investor EHA

    Jun 08 2020 · --Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that it has rescheduled its investor conference call

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    LONDON Sept. 08 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · Autolus Therapeutics to host Investor Conference Calls through June. After the conference call a replay will be available for one week. will host an investor call

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · LONDON May 26 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq AUTL) a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host investor conference calls through June 1 June 2020Dr. Christian Itin chairman and chief executive officer along with the AUTO3 clinical team will host an investor

    Get Price
  • Autolus Therapeutics to host Investor Conference Calls

    May 26 2020 · LONDON May 26 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc () a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies today announced that management will host investor conference calls through June 1 June 2020Dr. Christian Itin chairman and chief executive officer along with the AUTO3 clinical team will host an investor call

    Get Price
  • Autolus Therapeutics to host Investor Conference Call to

    Nov 17 2020 · Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare

    Get Price

Related Posts

  • medium frequency induction melting furnacemedium frequency induction melting furnace
  • fireplace maintenance toolscastable refractory grey
  • how to solve the phenomenon on the surface of refractoryrefractory castable high temperature castable refractory
  • refractory cements and moldables inhigh temperature refractory castable for heat treatment
  • main 2 occupational stress employment
  • the mechanism of mg2 conduction in ammine magnesium
  • how to make fire clay
  • marine acoustic insulation high performance
  • 3000 degree castable refractory cementcastable refractory mix
  • the influence of citric acid on setting time and

Product Center

  • Alumina Hollow Ball Bricks
  • Corundum Spinel Castable
  • High Alumina Refractory Cement
  • High Alumina Low Cement Castable
  • High Alumina Refractory Ramming Mass
  • Trough Refractory Castable
  • Magnesium Iron Spinel Brick
  • Mullite Brick
  • Zirconium Mullite Brick

Hot Products

  • Light Weight Silica Insulation Brick
  • Zirconia Hollow Sphere Brick
  • Corundum Refractory Castable
  • Heavy Alkali Resistant Castable
  • High Alumina Low Cement Castable
  • High Alumina Self Flowing Castable
  • Micro Expansion Refractory Plastic
  • Phosphate Refractory Mud
  • Magnesia Zircon Brick

Images Show

About Us

Rongsheng's main products are various types of unshaped refractory products, which are widely used in metallurgy, nonferrous metals, building materials, electric power, petrochemical and other industries.

Rongsheng pays attention to technological innovation and product research and development, and has established close cooperative relations with many universities and scientific research institutes.

Zhengzhou Rongsheng Company © Copyrights. Sitemap